N/A N=34 A System and Process to Improve the Satisfaction With Hearing Health Products
Hearing Loss
Primary: COSI Goal Achievement — 2.77; 2.51 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=244 A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin
Common Cold · Cough
Primary: Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score — -9.56; -9.11; -26.49; -22.97 score on a scale
N/A N=150 Live Long Walk Strong (LLWS) Rehabilitation Program: What Features Improve Mobility Skills
Mobility Limitation
Primary: Walking Speed — 0.86; 0.91 m/s
N/A N=20 Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers
Fatigue · Stress, Job
Primary: Qualitative Assessment of Intestinal Microbiota in Stool Samples
Phase 2 N=24 Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
Primary Sjögren's Syndrome
Primary: Number of Participants With TEAEs, TESAEs and TEAESIs — 15; 6; 0; 2 Participants
Phase 3 N=12 Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age
Von Willebrand Disease
Primary: Total Annualised Bleeding Rate (TABR) During Prophylactic Treatment With Wilate. — 4.6; 3.7 Annualized number of bleeding episodes
N/A N=1,672 Bridging the Childhood Epilepsy Treatment Gap in Africa
Epilepsy
Primary: Percentage Seizure-free for 6 Months, or Longer, Measured at 24 Months After Enrollment — 371; 299 Participants — p=0.11
N/A N=80 Effect of Recruitment Maneuver on Postoperative Atelectasis Assessed by Lung Ultrasound in Laparoscopic Cholecystectomy
Pulmonary Atelectasis
Primary: Change in Lung Ultrasound Score (LUS) — 5.2; 5.4; 8.7; 12.5 points — p=<0.001
Phase 3 N=33 Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
Macrophage Activation Syndrome · Secondary Hemophagocytic Lymphohistiocytosis · Still Disease
Primary: Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab — 11; 4 Participants
N/A N=1,139 OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.
Acute Coronary Syndrome · Myocardial Infarction
Primary: Optimisation of the Intensity of Lipid Lowering Therapy Within 16 Weeks of Index ACS — 369; 398; 145; 207 Participants
Phase 3 N=182 Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)
Chronic Sinusitis · Chronic Rhinosinusitis (Diagnosis)
Primary: Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps — -2.73; -1.61 Change from Baseline in…
N/A N=20 Prehospital Telemedicine Feasibility/Acceptability Pilot
Respiratory Distress Syndrome
Primary: Agreement in Assessment of Respiratory Distress — 0.83 proportion agreement
N/A N=58 Intensive Aerobic and Resistance Exercise Program (IAREP)
Type 2 Diabetes Mellitus · Cognitive Impairment · Non-insulin-dependent Diabetes Mellitus
Primary: Change in Cognitive Function Based on Risk Stratification Score (RSS) — -0.2; -0.1; -0.8; 0.0 score on a scale
N/A N=30 Labor and Delivery Doula Program to Reduce Perinatal Morbidity and Mortality in Kansas
Pregnancy Related · Doula Care · Black Maternal and Infant Health
Primary: Perceptions of Provider Communication — 1.42; 1.86 score on a scale
N/A N=399 Effectiveness of Transdiagnostic Cognitive Behavioral Therapy for Improving HIV Treatment Outcomes in South Africa
HIV/AIDS · Violence
Primary: 12 Month Viral Suppression — 86; 86 Participants